Clinical trial
An Efficacy and Safety Study of CNTO 1275 Compared to Etanercept in Patients…
NCT00454584 · Centocor, Inc., Industry · Completed
Key facts
| NCT number | NCT00454584 |
|---|---|
| Title | An Efficacy and Safety Study of CNTO 1275 Compared to Etanercept in Patients With Plaque Psoriasis |
| Official title | A Phase 3, Multicenter, Randomized Study Comparing CNTO 1275 and Etanercept for the Treatment of Moderate to Severe Plaque Psoriasis |
| Lead sponsor | Centocor, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Psoriasis |
| Intervention type | Drug |
| Interventions | CNTO 1275 45 mg, CNTO 1275 90 mg, Etanercept 50 mg |
| Enrollment | 903 |
| Start date | Mar 1, 2007 |
| Primary completion | Jan 1, 2008 |
| Completion | Jan 1, 2009 |
| First posted | Mar 30, 2007 |
| Last update posted | Nov 21, 2012 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: